Skip to content

US · TGTX · BIOTECHNOLOGY

TG Therapeutics, Inc. (TGTX) intrinsic value and stock valuation

$63.34as of 2026-11-21 · Mkt cap 7.64B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

TG Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values TGTX with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from TGTX’s statements →

TG Therapeutics, Inc. Graham Number

Graham Number: $17.69d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Morrisville, NY 27560 tgtherapeutics.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$616.3M+428.1% 5y CAGRd
20112025
Net income
$447.2M
20112025
Free cash flow
-$-24.99M
20112025
Total equity
$648M+4.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$616.3M$329M$233.7M$2.79M$6.69M
Operating income$123.3M$41.9M$20.6M-$-218.32M-$-344.77M
Net income$447.2M$23.4M$12.7M-$-223.81M-$-348.1M
EPSd$2.77M$145.8K$85.3K-$-1.65M-$-2.63M
Operating cash flow-$-24.77M-$-40.52M-$-31.41M-$-176.17M-$-295.63M
Capital expenditure-$-210K-$-40K$0.00-$-10K-$-400K
Free cash flow-$-24.99M-$-40.56M-$-31.41M-$-176.18M-$-296.04M
Total assets$1.06B$577.7M$329.6M$193.6M$379.6M
Total debt$260.7M$253.7M$110.8M$83.1M$79.1M
Net debt$181.6M$73.8M$17.9M-$-19.24M-$-219.84M
Total equity$648M$222.4M$160.5M$58.6M$237.2M
Cash and short-term investments$142M$311M$217.5M$161.7M$314.8M
Income statement
20252024202320222021
Revenue$616.3M$329M$233.7M$2.79M$6.69M
Cost of revenue$100.7M$38.5M$14.1M$270K$790K
Gross profit$515.6M$290.5M$219.5M$2.52M$5.9M
Research and development expenses$160.2M$94.3M$76.2M$125.4M$222.6M
Selling, general and administrative expenses$232M$154.3M$122.7M$95.5M$128.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$392.3M$248.6M$198.9M$220.8M$350.7M
Cost and expenses$493M$287.1M$213M$221.1M$351.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$26.7M$24M$12.6M$10.2M$5.64M
Depreciation and amortization$240K$280K$420K$520K$490K
Ebitda$134.4M$49.9M$26.1M-$-213.11M-$-341.97M
Operating income$123.3M$41.9M$20.6M-$-218.32M-$-344.77M
Total other income/expenses, net-$-15.93M-$-16.34M-$-7.57M-$-5.5M-$-3.33M
Income before tax$107.4M$25.6M$13.1M-$-223.81M-$-348.1M
Income tax expense-$-339.79M$2.21M$390K$0.00$0.00
Net income$447.2M$23.4M$12.7M-$-223.81M-$-348.1M
Weighted average shares outstanding$144.3M$145.3M$142M$135.4M$132.2M
Weighted average diluted shares outstanding$161.4M$160.3M$148.5M$135.4M$132.2M
Balance sheet
20252024202320222021
Cash and short-term investments$142M$311M$217.5M$161.7M$314.8M
Net receivables$305.6M$129.2M$51.1M$0.00$1.39M
Inventory$125.6M$110.5M$39.8M$0.00$0.00
Total current assets$630.8M$566.4M$317.9M$168.3M$331M
Property, plant and equipment, net$6.28M$7.15M$8.14M$10.8M$11.1M
Goodwill and intangible assets$0.00$0.00$800K$800K$800K
Long-term investments$59.1M$810K$1.28M$12.4M$35.5M
Total non-current assets$432.5M$11.3M$11.6M$25.3M$48.7M
Total assets$1.06B$577.7M$329.6M$193.6M$379.6M
Accounts payable$107.5M$0.00$0.00$0.00$0.00
Short-term debt$1.04M$1.16M$1.45M$1.58M$2.41M
Deferred revenue$21.2M$11.4M$150K$0.00$0.00
Total current liabilities$153.8M$90.7M$53.7M$53.2M$65.4M
Long-term debt$259.7M$252.6M$109.4M$81.5M$76.6M
Deferred revenue, non-current$8.81M$12.1M$6.02M$300K$460K
Total non-current liabilities$261.5M$264.7M$115.4M$81.8M$77.1M
Capital lease obligations$7.02M$9.29M$10.7M$11.9M$11.3M
Total liabilities$415.2M$355.3M$169.1M$135M$142.5M
Common stock$160K$160K$150K$150K$140K
Retained earnings-$-1.08B-$-1.53B-$-1.55B-$-1.53B-$-1.33B
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$648M$222.4M$160.5M$58.6M$237.2M
Total investments$122M$131.9M$125.9M$71.8M$51.4M
Total debt$260.7M$253.7M$110.8M$83.1M$79.1M
Net debt$181.6M$73.8M$17.9M-$-19.24M-$-219.84M
Cash flow statement
20252024202320222021
Net income$447.2M$23.4M$12.7M-$-198.34M-$-348.1M
Depreciation and amortization$60K$280K$420K$520K$490K
Stock-based compensation$64.7M$42.5M$37.9M$19.2M$61.3M
Change in working capital-$-194.54M-$-109.3M-$-84.66M-$-1.65M-$-12.22M
Accounts receivable-$-176.44M-$-78.09M-$-51.09M$1.39M-$-1.39M
Inventory-$-33.45M-$-66.85M-$-36.94M$0.00-$-15.99M
Accounts payable$55.9M$0.00$190K-$-11.01M$16M
Net cash provided by operating activities-$-24.77M-$-40.52M-$-31.41M-$-176.17M-$-295.63M
Investments in property, plant and equipment-$-210K-$-40K$0.00-$-10K-$-400K
Acquisitions, net$0.00$0.00$0.00$20M-$-70K
Net cash used for investing activities$13.8M-$-1.04M-$-50.65M-$-20.01M-$-330K
Common stock issued$1.51M$0.00$46.3M$580K$2.22M
Common stock repurchased-$-91.24M-$-8.76M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-89.73M$128.5M$72.7M-$-390K$41.4M
Net change in cash-$-100.7M$87M-$-9.36M-$-196.57M-$-254.55M
Cash at end of period$80.5M$181.2M$94.2M$103.6M$300.2M
Operating cash flow-$-24.77M-$-40.52M-$-31.41M-$-176.17M-$-295.63M
Capital expenditure-$-210K-$-40K$0.00-$-10K-$-400K
Free cash flow-$-24.99M-$-40.56M-$-31.41M-$-176.18M-$-296.04M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About TG Therapeutics, Inc.

        Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.

        CEO
        Michael S. Weiss
        Employees
        399
        Beta
        1.60

        Explore

        Frequently asked questions

        What is the intrinsic value of TG Therapeutics, Inc. (TGTX)?

        TG Therapeutics, Inc. (TGTX) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TGTX undervalued?

        TGTX trades at a price of $63.34 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.